The Pharmaceutical care of AIDS Patients Using Triple Antiretroviral Therapy in Surin Hospital
Article Sidebar
Main Article Content
Abstract
Background: HIV and AIDS patients increase rapidly causing public health problems to every country all over the world. Many efforts are put to reduce, control and eliminate AIDS crisis. MSF together with CDC and Surin Hospital launched a program. Triple antiretroviral therapy trying to prolong AIDS patients lives. Therefore, the study of The Pharmaceutical care of AIDS patients using Triple antiretroviral therapy in Surin Hospital is vital and can help guiding any researchers who are interested in the program.
Research Design: Prospective descriptive Study.
Objective: This study is follow up and to pinpoint problems occurred by using Triple antiretroviral therapy among AIDS patients in Surin Hospital.
Method: The sample group is 12-60 of age and the group size is 39 ; male : female with ratio of 26:13 during April - September 2001
Results: It is found that 31 patients used Triple antiretroviral therapy continuously while 8 patients stopped using them since 3 got ADR, 3 died and 2 loss of follow up. The CD and weight of those who keep using drugs raised up (66.67%) and (58.97%) respectively. All case found drug-related problems and the most reported problems were ADR (67.91%), drug interaction (21.93%) and discontinuation the therapy (7.49%).The anti-retroviral drugs which mostly reported to cause ADR were INDINAVIR and RITONAVIR (24.80%) and the most frequent reported symptom were nausea and vomiting (19.64 %). 13 of case experienced serious ADR. Drug interaction were found in 16 couples of concomitant drugs therapy; neither of them had major severity level. The cost of using antiretroviral drugs per patients per month is around 5,916 -12,078 Bath.
Conclusion: AIDS patients almost always consume too many medications, which even cause complexity of predicting and adjusting for drug interaction and adverse drug reaction. Since all cases had drug-related problems. Thus, Pharmacists, playing a major role should take time to review carefully each patients medication.
Article Details
References
2. สำนักงานควบคุมโรคติดต่อ เขต 10 เชียงใหม่. แนวทางการปฏิบัติงานเภสัชกรรมคลินิก และการบริหารเวชภัณฑ์ ในการบำบัดรักษาผู้ติดเชื้อด้วยยาต้านไวรัสเอดส์ตามโครงการพัฒนาระบบบริการและ ติดตามผลการดูแลรักษาผู้ป่วยติดเขึ้อ เอชไอ วี และผู้ป่วยเอดส์ในประเทศไทย. เชียงใหม่ : มปป, 2544.
3. สุเทพ จารุรัตนศิริกุล. ปฏิกิริยาต่อกันของ ยาต้านเภสัชจลนศาสตร์ในผู้ป่วยเอดส์. กรุงเทพฯ : โอ เอส พริ้นติ้ง เฮาส์, 2542.
4. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998 : Update recommendations for the international AIDS Society-USA panel. JAMA 1998 ; 280 : 78-86.
5. Charles F. Lacy, Lora L. Armstrong, Morton p. Goldman, Leonard L. Lance, editors. Drug information handbook. 8 th ed. 2000 -2001.
6. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice. St.Louis (MO) : McGraw-Hill ; 1998.
7. Barbara G. Wells, Josepph T. DiPiro, Terry L. Schwinghammer, Cindy W.Hamilton, editors. Pharmacotherapy handbook. Stamford Connecticut : Appleton & Lange ; 1998.
8. Frederic J. Zucchero, Mark J. Hogan, Christine D. Schultz. American Pharmaceutical Association. Washington, DC. Pocket Guide to Evaluations of Drug Interaction. 3rd ed. 1999.
9. Lisa I. Malaty, Jeffrey J. Kuper. Drug Interaction of HIV Protease Inhibitors : Drug Safety 1999 p. 148 -169.
10. Milo Gibaldi, et al. Drug Therapy 2000 : Acritical Review of Therapeutics. Me Graw-Hill ; 2000 p. 132134
11. UNAIDS/WHO. Report on the global HIV/AIDS epidemic, June 1998.
12. US. Department of Health & Human Services. Guidelines for the Prevention of opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. MMWR. August 20, 1999/Vol. 48.
